Efficacy and Safety of 24 Weeks of Therapy with Bendroflumethiazide 1.25???mg/day or 2.5???mg/day and Potassium Chloride Compared with Enalapril 10???mg/day and Amlodipine 5???mg/day in Patients with Mild to Moderate Primary Hypertension

Rasmussen, S; Borrild, Niels Jerne; Andersen, J Vang

doi:10.2165/00044011-200626020-00004

Cited by 5 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ten were double-blind, and one was single-blind. A placebo washout period (between 4 and 8 weeks) was used in 9 of the studies (Applegate et al, 1991;Croog et al, 1990;Dahlof et al, 1997Dahlof et al, , 2005Omvik et al, 1993;Rake et al, 2001;Rasmussen et al, 2006;Steiner et al, 1990). The follow-up time varied from 6 weeks to 7 years from the start of active treatment to the completion of the trial.…”

Section: Resultsmentioning

confidence: 99%

“…Psychological General Wellbeing Index. The Psychological General Wellbeing (PGWB) index, used in eight studies (Applegate et al, 1991;Croog et al, 1990;Dahlof et al, 1997Dahlof et al, , 2005Omvik et al, 1993;Rake et al, 2001;Rasmussen et al, 2006;Steiner et al, 1990), is designed to assess six domains to determine quality of life: anxiety, depressed mood, positive well-being, self-control, general health and vitality (Wiklund and Karlberg, 1991). The index consists of 22 questions, with each question being scored from 1 to 6, giving a total minimum of 22 and maximum of 132, with a higher score indicating better outcomes.…”

Section: General Outcomesmentioning

confidence: 99%

See 1 more Smart Citation

Blockade of the angiotensin system improves mental health domain of quality of life: A meta-analysis of randomized clinical trials

Brownstein

Salagre

Köhler

et al. 2017

Aust N Z J Psychiatry

View full text Add to dashboard Cite

Use of angiotensin blockers and inhibitors for the treatment of hypertension in otherwise healthy adults is associated with improved mental health domains of quality of life. Mental health quality of life was a secondary outcome in the included studies. Research specifically designed to analyse the usefulness of drugs that block the angiotensin system is necessary to properly evaluate this novel psychiatric target.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: General Outcomesmentioning

confidence: 99%

Blockade of the angiotensin system improves mental health domain of quality of life: A meta-analysis of randomized clinical trials

Brownstein

Salagre

Köhler

et al. 2017

Aust N Z J Psychiatry

View full text Add to dashboard Cite

show abstract

“…The study showed a tendency of increased mortality and non-fatal myocardial infarction in the group receiving atenolol and bendroflumethiazide and potassium, though it was not significant [20]. Another RCT assigned participants with mild to moderate essential hypertension to one of the four groups, (i) bendroflumethiazide 1.25 mg/day and potassium chloride, (ii) bendroflumethiazide 2.5 mg/day and potassium chloride, (iii) amlodipine 5 mg/day, or (iv) enalapril 10 mg/day, to compare the efficacy and safety of treatments [21]. The trial found that all treatments reduced diastolic blood pressure; however, the reduction in the diastolic blood pressure on amlodipine was significantly higher than on the three other treatment combinations [21].…”

Section: Discussionmentioning

confidence: 99%

Calcium Channel Blockers and the Risk of Exacerbation in Patients with Chronic Obstructive Pulmonary Disease: A Nationwide Study of 48,488 Outpatients

et al. 2023

View full text Add to dashboard Cite

Patients with chronic obstructive pulmonary disease (COPD) are prone to developing arterial hypertension, and many patients are treated with the calcium channel blocker amlodipine. However, it remains unclear whether using this drug potentially affects the risk of acute severe exacerbations (AECOPD) and all-cause mortality in these patients. The data were collected from Danish national registries, containing complete information on health, prescriptions, hospital admissions, and outpatient clinic visits. The COPD patients (n = 48,488) were matched via propensity score on known predictors of the primary outcome in an active comparator design. One group was exposed to amlodipine treatment, and the other was exposed to bendroflumethiazide, since both of these drugs are considered to be the first choice for the treatment of arterial hypertension according to Danish guidelines. The use of amlodipine was associated with a reduced risk of death from all causes at the 1-year follow-up (hazard ratio 0.69, 95% confidence interval: 0.62–0.76) compared with the use of bendroflumethiazide in the matched patients. No difference in the risk of severe AECOPD was found. In the COPD patients, amlodipine use was associated with a lower risk of death from all causes compared with the use of bendroflumethiazide. Amlodipine seems to be a safe first choice for the treatment of arterial hypertension in COPD patients.

show abstract

“…Thiazides were compared with the placebo (n = 15 comparisons), [22][23][24][25][26][27][28][29][30][31][32][33][34][35][36] BB (n = 13), [37][38][39][40][41][42][43][44][45][46][47][48][49] CCB (n = 12), 17,20,25,39,42,48,[50][51][52][53][54][55] RAASi (n = 28), 20,23,39,42,48,50,[56][57][58][59][60][61][62]…”

Section: Study Characteristicsmentioning

confidence: 99%

Thiazide Diuretic–Induced Change in Fasting Plasma Glucose: a Meta-analysis of Randomized Clinical Trials

et al. 2020

View full text Add to dashboard Cite

BACKGROUND: Prior meta-analyses measuring thiazideinduced glycemic change have demonstrated an increased risk of incident diabetes; however, this measure's definition has changed over time. AIM: To determine the magnitude of change in fasting plasma glucose (FPG) for thiazide diuretics. DATA SOURCES: A research librarian designed and conducted searches in Medline®, EMBASE, and EBM Reviews-Cochrane Central Register of Controlled Trials (inception through July 2018) and International Pharmaceutical Abstracts (inception to December 2014). STUDY SELECTION: Randomized, controlled trials comparing a thiazide or thiazide-like diuretic to any comparator reporting FPG were identified. Trials enrolling < 50 participants, those with a follow-up period of < 4 weeks, and conference abstracts were excluded. DATA EXTRACTION: Independent duplicate screening of citations and full-text articles, data extraction, and assessment of risk of bias was conducted. DATA SYNTHESIS: Ninety-five studies were included (N = 76,608 participants), with thiazides compared with placebo, beta-blockers, calcium channel blockers, reninangiotensin-aldosterone-system inhibitors, potassiumsparing diuretic, and others alone or in combination. Thiazide diuretics marginally increased FPG (weighted mean difference 0.20 mmol/L (95% CI 0.15-0.25); I 2 = 84%) (1 mmol/L = 18 mg/dL). Results did not change substantially when considering dose or duration, comparing thiazides with placebo or an active comparator, or using thiazides as monotherapy or combination therapy, even when combined with a potassium-correcting agent. CONCLUSION: Thiazide diuretics have a small and clinically unimportant impact on FPG.

show abstract

Efficacy and Safety of 24 Weeks of Therapy with Bendroflumethiazide 1.25???mg/day or 2.5???mg/day and Potassium Chloride Compared with Enalapril 10???mg/day and Amlodipine 5???mg/day in Patients with Mild to Moderate Primary Hypertension

Cited by 5 publications

References 15 publications

Blockade of the angiotensin system improves mental health domain of quality of life: A meta-analysis of randomized clinical trials

Blockade of the angiotensin system improves mental health domain of quality of life: A meta-analysis of randomized clinical trials

Calcium Channel Blockers and the Risk of Exacerbation in Patients with Chronic Obstructive Pulmonary Disease: A Nationwide Study of 48,488 Outpatients

Thiazide Diuretic–Induced Change in Fasting Plasma Glucose: a Meta-analysis of Randomized Clinical Trials

Contact Info

Product

Resources

About